ADVERTISEMENT

Medtech 100

MTI 100 Feature: Manufacturing Devices In The Rollercoaster UK Market

MTI 100 Feature: Manufacturing Devices In The Rollercoaster UK Market

A scale-up strategy is the missing link in the UK devices industry, claims business research organization CPI. Own brand and contract medical manufacturer and packaging company Pennine Healthcare, and longstanding medical device CDMO Renfrew Group International, give their take on the environment for manufacturers and the opportunities for strengthening the industry base.

MTI 100: Macro Challenges Make Demands Of Newly Resilient Medtechs

MTI 100: Macro Challenges Make Demands Of Newly Resilient Medtechs

Global medtechs had a big enough challenge with COVID-19 and its aftermath before the full-scale regional conflict in Ukraine added more uncertainty to the question of when market normality would return.

MTI 100: Global Medtech Recovers Core Growth After A Year Like No Other

MTI 100: Global Medtech Recovers Core Growth After A Year Like No Other

With many medtechs restructuring for core growth in the post-pandemic era, Abbott relied on organic growth in 2022 to move to the top of the global medtech ranking. The strength of the US dollar was not kind to companies reporting in local currencies on converting revenues to dollars.

MTI 100 Outlook 2024: Shaping An Environment Where Technology Leads The Way

MTI 100 Outlook 2024: Shaping An Environment Where Technology Leads The Way

Compliance with greenhouse gas reduction targets is not optional for medtech businesses who, besides the bigger picture, have their own sustainability to think of. Environmental demands, the evolution of care models, new delivery technologies and AI tools are influencing how medtechs must approach innovation. In the EU, the MDR is also having an effect on innovation strategies.

MTI 100: The Medtech Industry In Revenues

MTI 100: The Medtech Industry In Revenues

The latest MT100 listings are now published on Medtech Insight.

Medtech 100: For Edwards Lifesciences' Mike Mussallem, Inspiring People Has Been A Way Of Life

Medtech 100: For Edwards Lifesciences' Mike Mussallem, Inspiring People Has Been A Way Of Life

Edwards Lifesciences CEO Mike Mussallem has a unique and long-standing perspective of what the medtech industry should be and do. In over two decades, he has built the structural heart disease and critical care monitoring company into one of the global medtech industry’s most effective innovators. That legacy is sure to last after his retirement as CEO in spring 2023.  

Medtech 100: Why Patient-Centered Care Has To Change

Medtech 100: Why Patient-Centered Care Has To Change

A typical word cloud for discussions around patient-centered care would feature: business model, digital health, financing, PPP, resources, data sharing, staffing and escalation of costs. But so many other words are missing, which is why patient-centricity risks getting stuck in its current incomplete form. What are medtechs to do?  

Medtech 100 - EU Outlook 2023: Will The Road Ahead Be Any Smoother For The EU’s Medtech Regulations?

Medtech 100 - EU Outlook 2023: Will The Road Ahead Be Any Smoother For The EU’s Medtech Regulations?

Originally intended to increase medical device safety, the implementation of the EU’s medtech regulation was so hampered in 2022 that it had started to look as if the new regulations were a bigger potential threat to patients than any of the scandals leading to its more stringent requirements. With the European Commission’s latest plans to ease challenges around implementation, will 2023 be a more positive year for the EU medtech sector?

Podcast: Medtech 100 And 2023 Outlook Published

Podcast: Medtech 100 And 2023 Outlook Published

Medtech Insight’s annual listing of the leading medtech companies by revenues is now available on the Medtech Insight website.

Outlook 2023: The Irresistible Forces Shaping Medtech Markets And Industry

Outlook 2023: The Irresistible Forces Shaping Medtech Markets And Industry

The integration of smart connected care, broadening of diagnosis and therapy into new settings and improvement of chronic disease outcomes will continue to shape the market for devices and diagnostics companies for years to come. But there is also a maze of short-term macroeconomic issues for medtechs to work through.